The cost-utility analysis of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: a probabilistic decision model  by Uthman, Olalekan A. et al.
T
p
s
O
T
I
O
a
B
b
c
d
K
C
M
H
P
S
(
1
P
d
V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 0 - 7 9
avai lable at www.sc iencedirect .com
journal homepage: www.elsevier .com/ locate / jva lhe cost-utility analysis of adult male circumcision for
revention of heterosexual acquisition of HIV in men in
ub-Saharan Africa: a probabilistic decision model
lalekan A. Uthman, MD, MPHa,*,
aiwo Aderemi Popoola, BMR(physiotherapy) MSc(EBH & HTA)b,
smail Yahaya, MBBS, MPHa, Mubashir M. B. Uthman, MBBS, MPH, FWACPc,
latunde Aremu, BPharm MPHd
The West Midlands Health Technology Assessment Collaboration (WMHTAC), University of Birmingham, Public Health, Epidemiology &
iostatistics, Edgbaston, Birmingham, UK
Center for Evidence-Based Global Health, Nigeria
Department of Community Health and Epidemiology, University of Ilorin, Ilorin, Nigeria
College of Medicine, University of Ibadan, Ibadan, Nigeria
eywords:
ost-utility analysis
ale circumcision
IV/AIDS
robabilistic model
ub-Saharan Africa
A B S T R A C T
Objective: The aim of this study was to assess the cost-utility of adult male circumcision
(AMC) versus no AMC in the prevention of heterosexual acquisition of HIV in men in sub-
Saharan Africa.
Methods: A decision tree was constructed and parameterized using data from published
sources. The economic evaluation was conducted from the perspective of government
health care payer. Benefits (disability adjusted life years [DALYs]) and costswere discounted
at 3%. Costs were assessed in 2008 US dollars. One-way and probabilistic sensitivity analy-
ses were conducted to assess the stability of the base-case results. The uncertainty sur-
rounding the estimates of cost effectiveness was illustrated through a cost-effectiveness
acceptability curve and cost-effectiveness plane.
Results: In the base-case analysis, AMC can be regarded as cost saving because it is associated
with higher DALYs gained and lower costs than no AMC. The probability that AMC is cost
effective is above 0.96 at a threshold value of $150 and remains high over a wide range of
threshold values. Thus, there is very little uncertainty surrounding the decision to adopt AMC
for prevention of heterosexual acquisition ofHIV inmen. The resultswere found to be sensitive
to varying anyof the followingparameters:DALYsaverted, discount, and circumcision efficacy.
Conclusions: AMC is found to be cost saving. AMCmay be seen as a promising new form of
strategy for prevention of heterosexual acquisition of HIV in men, but should never replace
other known methods of HIV prevention and should always be considered as part of a
comprehensive HIV prevention package.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research
(ISPOR). Published by Elsevier Inc.
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uman immunodeficiency virus (HIV)/acquired immunode-
ciency syndrome (AIDS) accounts for about 20% of all
eaths and disability adjusted life year (DALY) lost in Africa
1]. The cost of the AIDS epidemic is incurred not only in
ollars, but also in the suffering and death of friends, fam-
ly, and loved ones. The loss to society is untold. The conti-
ent has lost productivity and creativity, as well as health
nd social service dollars. Of the estimated 33 million peo-
le infected with HIV worldwide, about half are men, most
f whom have become infected through heterosexual inter-
ourse [1]. There is conclusive evidence from observational
ata [2] and three randomized controlled trials [3–5] that
ircumcised men have a significantly lower risk of becom-
ng infected with the HIV. There is evidence to support the
iological basis for the protective effect of circumcision on
IV transmission. The uncircumcised penis consists of the
enile shaft, glans, urethral meatus, inner and outer surface
f the foreskin, and the frenulum [6]. Penile shaft and outer
urface of the foreskin are covered by a keratinized, strati-
ed squamous epithelium [6]. The inner mucosal surface of
he foreskin is not keratinized and is rich in Langerhans’
ells (potential HIV receptors) [7], making it particularly sus-
eptible to the virus. The foreskin is retracted down to the
haft of the penis during heterosexual intercourse and the
hole inner surface of the foreskin is exposed to vaginal
ecretions, providing a substantial area where HIV trans-
ission could take place [6].
New approaches to combat the pandemic are particu-
arly welcome in light of United Nations’ estimates that al-
ost 5 million people become infected with HIV, and more
han 2 million people die of AIDS, each year [1]. Innovations
n antiretroviral drug treatment have invigorated interna-
ional efforts to curb the annual burden of AIDS deaths, but
reventing new infections remains the key to breaking the
ack of the epidemic and curtailing the expanding need for
reatment [8]. Several innovations demonstrate promise for
educing the efficiency of HIV transmission [9]. However, for
ny of these approaches to reduce the rate of new infec-
ions, they must reach sufficient numbers of people who are
ikely to transmit or acquire infection, and their protective
enefits must not be offset by increased riskier behavior in
he targeted community [9,10]. Because population inter-
entions can reach large numbers of at-risk persons inex-
ensively, they have the potential to be highly cost effective
10]. HIV prevention is still our best hope for fighting the
IV/AIDS epidemic. There is evidence to suggest that adult
ale circumcision (AMC) can be a cost-effective strategy for
revention of heterosexual acquisition of HIV in men. Sev-
ral economic evaluations [11–15] have shown that AMC is
ost effective, or even cost saving (a cost-saving interven-
ion is one that actually saves society money in the long run
y preventing costly medical care) for the prevention of het-
rosexual acquisition of HIV in men. A preliminary exami-
ation of the existing economic evaluations suggests that,
tudies have tended to focus on population in a limited geo-
raphic area, have expressed results in terms of cost per HIV vnfection averted (HIA), or have not considered DALYs [16].
ost of these studies did not include impact of complica-
ions association with AMC in their models [16]. Except for
ahn et al. [15], most of the authors did not consider multi-
ariate sensitivity analysis. Simple series one-way sensitiv-
ty analyses cannot provide enough insight into the scale of
ecision uncertainty [17]. In many models, the uncertainty
n the individual parameters may be very unlikely to change
decision. The way to understand the implications for de-
ision uncertainty of imprecisely estimated parameters is
o include all of those parameters subject to uncertainty in
he sensitivity analysis, and to use the full distributions of
hose parameters based on all available evidence [17]. This
s not possible with simple one-way sensitivity analysis.
To examine these issues further, the present study reports
he results of a cost-utility analysis of AMC for the prevention
f heterosexual acquisition of HIV in men. The model was
opulated using data derived from three randomized trials
nd other sources, and then calibrated probabilistically to rep-
esent the joint uncertainty in the input parameters.
ethods
odel structure
e designed a decision-treemodel to compare costs and ben-
fits of AMC, which is outlined in Figure 1. The prevention
trategy, male circumcision, is compared to a “no-program”
ption, in which AMC is not offered. The AMC has been de-
cribed elsewhere. The target population includes all adult
ale in sub-Saharan Africa. The study assesses the lifetime
osts and effects of male circumcision for the prevention of
eterosexual acquisition of HIV in men. The time frame is,
herefore, lifetime because we estimate there is an expected
ifetime of medical care costs for HIV/AIDS. The analytical ho-
izon also includes all of the future benefits, DALY averted
ssociated with each case of HIV infection averted. This anal-
ig. 1 – Base-case decision tree for adult male circumcision
ersus no adult male circumcision.
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72 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 0 - 7 9sis adopts the perspective of a government health-care payer
n sub-Saharan Africa. We considered all direct programs and
edical costs. Health outcomes and cost accrued beyond 1
ear were discounted at 3% for the base-case analysis, 0% and
% were tested in sensitivity analysis. All cost data were con-
erted to US dollars and inflated to 2008 prices using price
nflation index. Results were presented as incremental cost-
ffectiveness ratio (ICER), mean incremental costs and effects,
ost-effectiveness planes (CE-plane), and cost-effectiveness
cceptability curves (CEACs). These were chosen to represent
he output uncertainty from probabilistic sensitivity analysis
PSA) within the decision-making context [18–19]. CEACs pro-
ide a measure of likelihood that a decision to apply a given
ntervention is correct across a range of “willingness-to-pay”
hresholds [18,19]. “Willingness-to-pay” in this context repre-
ents the maximum amount a decision maker is prepared to
ay for a gain of one DALY averted. The model was developed
sing the R programming language [20].
arameters
arameter estimates were extracted from published data.
able 1 presents the model input parameters and their
ources. The prevalence of HIV among uncircumcised male
as based on evidence from Demographic and Health Sur-
eys [21]. Only 12 countries with available data on HIV prev-
lence were included [21]. The rate of complications associ-
ted with AMC was estimated from nine published studies
3–5,22–27]. The study considered adverse events related to
urgery. The most common adverse events were postoper-
tive bleeding and infections. Other reported adverse
vents include: wound disruptions, delayed healing, and
welling at the incision site. We calculated the weighted
oint estimates for prevalence of HIV among uncircumcised
ale and rate of complication of AMC using meta-analysis.
e calculated the prevalence by calculating proportions
ith 95% confidence intervals (CIs) for each study and then
ooled the data to derive a pooled proportion with 95% CI.
Table 1 – Model parameters.
Parameters Deterministic mea
Probabilities
HIV among uncircumcised males (%) 5.05
Effect of male circumcision (OR) 0.43
Rate of complications (%) 10.99
ART coverage (%) 44
Cost
Male circumcision ($) 65.14
Treating complications ($) 15.48
Lifetime cost of treating HIV/AIDS
ART ($) 15,410.36
No ART ($) 3465.02
Utilities
DALY saved per HIV averted 15.50
Discount (%) 3
Time on treatment (years) 15
Note: $ - values in 2008 US dollars.
ART, antiretroviral therapy; DALY, disability adjusted life-years; OR, odds ror the purpose of proportion meta-analysis, the propor-
ions were first turned into a quantity (the Freeman-Tukey
ariant of the arcsine square root transformed proportion
28]) suitable for the usual fixed and random effects sum-
aries. The pooled proportion was calculated as the back-
ransform of the weighted mean of the transformed propor-
ions, using DerSimonian weights for the random effects
odel in the presence of significant heterogeneity [29]. Ef-
cacy of AMC was estimated from three large RCTs [3–5]
dentified in a recent Cochrane systematic review [30] using
xed and random-effect meta-analysis. The coverage of an-
iretroviral therapy (ART) was taken from a recent joint
nited Nations AIDS (UNAIDS) progress report. The cost of
MC and cost of treating complications associated with
MC were taken from the Orange Farm (OF) trial [3]. The
ifetime cost of HIV treatment was based on a recent study
n South Africa [15]. This study estimated a lifetime cost
ith ART and without ART. The study did not include non-
edical HIV/AIDS costs borne by the patients (e.g., the cost
f travel to receive treatment). DALY averted per HIV infec-
ions had been previously reported [13].
ensitivity analysis
o account for uncertainty around model input parameter val-
es, one-way and probabilistic sensitivities were carried out.
ne way-sensitivity (univariate) analyses were done by varying
he parameters according to the ranges in Table 1. Probabilities
ere varied over the ranges derived from their 95% CIs. Varia-
ions in costs, utility, discount, and time horizonswere based on
stimatedminimums andmaximums according to themethod-
logy described in recently published work [31]. If not available,
tandarderrorsweredefinedas25%of themean, so thata95%CI
ould be 50%more or less thanmean. Both low and high ICERs
ere recorded in univariate analyses.
A probabilistic sensitivity analysis (PSA) was performed to
emonstrate the robustness of the model against all input as-
umptions. Using Monte Carlo technique, all model parameters
Range Distribution Reference
2.25–8.89 Beta (19)
0.30–0.61 Lognormal (7–9)
5.62–17.86 Beta (7–9, 20–25)
41–48 Beta (48)
32.58–97.71 Normal (7)
7.74–23.22 Normal (7)
13,045.83–18,757.40 Normal (34)
3050.30–3905.45 Normal (34)
7.75–23.25 Uniform (12)
0–5 Uniform Assumed
10–20 Uniform Assumednatio.
w
t
c
t
w
A
b
s
a
u
l
c
c
m
t
w
i
o
s
b
H
c
e
R
F
R
s
v
t
7
A
e
t
2
a
c
w
o
t
(
s
n
c
$
l
r
5
o
p
l
e
t
t
i
m
2
p
m
c
t
m
c
F
e
73V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 0 - 7 9ere varied simultaneously according to pre-specified distribu-
ions. Distributions were assigned according to the inherent
haracteristics of eachparameter according to accepted conven-
ions. Beta distribution was used for all probabilities. All costs
ere assumed to follow a normal distribution. The efficacy of
MC was expressed as odds ratio (OR). We used log-odds ratio,
ecause lognormaldistributionasymptomaticallynormalize the
kewedOR.Uniformdistributionwasused for utilities, discount,
nd timehorizon.Resultswerebasedon10,000MonteCarlo sim-
lations.
Policy makers will wish to identify interventions that are
ess costly than the comparator and have better health out-
omes, called dominant, and rule out those that are more
ostly and less effective, termed dominated. More costly and
ore effective interventions may be selected if they are
hought to represent good value for money. An intervention
as defined as cost effective if it was dominant or had an
ncremental cost per DALY averted under US$150. The value
f US$150 was chosen in the base case, to represent a deci-
ion-maker’s valuation of a healthy year of life. This was
ased on recommendations of the Ad Hoc Committee on
ealth Research Priorities, which stated that any intervention
osting less than US$150 per DALY averted should be consid-
red attractive in low-income countries [32].
esults
igure 2 shows the odds ratio and 95% CIs from the individual
CTs [3–5] and pooled result. The meta-analysis demonstrated
tatistically significant superiority of AMC over no AMC in pre-
enting HIV infection (pooled OR0.43; 95% CI 0.30 to 61); such
hat participants that underwent AMC were 57% (95% CI 39% to
0%) less likely to be diagnosed with HIV than those without
ig. 2 – Forest plot of the odds ratios (ORs) and 95% confiden
ffectiveness of adult male circumcision for prevention of heteroMC. The pooled effect was identical assuming random or fixed
ffects. There was no significant statistical heterogeneity be-
ween the trial results (20.60;df2;P0.74and20.31;df
; P 0.86) with the degree of heterogeneity quantified by the I2
s 0% in both analyses. The prevalence of HIV among uncircum-
isedmales ranged from 0% in Senegal to 19% in Lesotho (Fig 3),
ith the pooled prevalence being 5% (95% CI 2% to 9%). The rate
f complications associatedwith AMC ranged from as low as 2%
o asmuch as 50% (Fig 4), with a pooled complication rate of 11%
95% CI 6% to 18%).
The expected costs andDALYs generated from themodel are
hown inTable 2. At base-case values of all parameters, the total
umber of DALY averted by the interventionwas 0.28. The base-
ase was associatedwith negative net costs (i.e., cost savings) of
91. Thus, AMC dominates no AMC because it is associatedwith
ower cost and higher DALY averted (cost saving). We tested the
obustness of the cost-effectiveness results extensively. Figures
and 6 depict the results of one-way sensitivity analysis when
ne parameter value was varied at a time while holding other
arameters at their base-case values. AMC was associated with
ower cost and higher DALY averted than no AMC for all param-
ters (dominates). However, incremental cost was most sensi-
ive to the variations in DALY, discount rate, and program effec-
iveness. DALY averted had the strongest impact on both
ncremental cost and utility. The incremental cost ranged from
inus US$206 to minus $4 when DALY was varied from 7.74 to
3.25. Varying complication rate andART coverage had little im-
act on the incremental cost.
Figure 7 presents the 10,000 simulations in terms of incre-
ental costs (y axis) and DALYs (x axis) and takes no AMC into
onsideration as the reference. A majority (89%) of incremen-
al cost-effect pairs fall in the southeast quadrant of the incre-
ental cost-effectiveness plane, indicating that the AMC is less
ostly andmore effective than the no AMC for the prevention of
tervals (CIs) of individual trials and pooled data force in
sexual acquisition of HIV in men.
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74 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 0 - 7 9eterosexual transmission of HIV in men. Proportions (11%) of
he points lie in the northeast quadrant, indicating that theAMC
smore costly and alsomore effective than the no AMC. Figure 8
resents the CEACs for the incremental cost per DALY averted.
ig. 3 – Forest plot of the prevalence of HIV among uncircum
tudies and pooled data.
ig. 4 – Forest plot of the rate of complications associated wi
ndividual studies and pooled data.s shown in Figure 8, if decision makers were willing to pay
S$150perDALY, theprobabilityofAMCbeingcosteffectivewas
.96. The probability of AMC being cost effectivewas 100%when
he willing to pay was US$500.
d men and 95% confidence intervals (CIs) of individual
ale circumcision and 95% confidence intervals (CIs) ofciseth m
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ain findings
e constructed a decision analytical model to evaluate the
ost effectiveness of AMC for the prevention of heterosexual
cquisition of HIV in men. The incremental cost effectiveness
as conducted from the perspective of the government
ealth-care payer. In the base-case analysis, AMC can be re-
arded as cost saving because it is associated with higher
ALYs gained and lower costs than noAMC. There is also little
ncertainty associatedwith this decision. The probability that
MC is cost effective is above 0.96 at a threshold value of
S$150 and remains high over a wide range of threshold val-
es. The sensitivity analyses found that the cost-effective out-
omes were not sensitive when varying any of the following
arameters: costs of treating complications, rate of AMC-as-
ociated complications, and prevalence of HIV among uncir-
umcised males. The results were found to be sensitive to
arying any of the following parameters: DALYs averted, dis-
ount, and circumcision efficacy.
Table 2 – Incremental cost-effectiveness ($/DALY) results fo
Strategy Cost Incremental cost
Deterministic
No male circumcision 282.87
Male circumcision 191.76 91.11
Mean – PSA
No male circumcision 266.49
Male circumcision 186.86 79.63
PSA – probabilistic sensitivity analysis
* Dominates- means adult male circumcision is cost-saving as it is asFig. 5 – Tornado plot for incremental cost. ART, antiretrotrengths and limitations of the study
his model provided a more favorable cost effectiveness out-
ome for AMC than the previously published economic eval-
ations in this area. To the best of our knowledge, this is the
rst model to incorporate probabilistic sensitivity analysis to
ive a comprehensive estimate of uncertainty associated with
MC and based results from pooled data from the three large
rials. Decision analyticalmodels provided several advantages
ompared with economic evaluations alongside clinical trials;
vidence frommultiple sources can be combined and system-
tic sensitivity analyses done [33]. The prevalence HIV among
ncircumcised males and complication rates were based on
eta-analysis of several studies from sub-Saharan Africa.
his study compared the costs and outcomes of the AMCwith
hat would be expected without any intervention. Compari-
onwith no AMC allows the cost effectiveness of thismodel of
MC to be compared with any other intervention in health,
nd not just to be considered as an incremental change to
lternative HIV prevention strategies [34]. This method of
omparing a health-care intervention with the hypothetical
lternative of doing nothing, and using probabilistic sensitiv-
ult male circumcision versus no adult male circumcision.
DALYs Incremental DALY ICER ($/DALY)
9.45
9.73 0.28 Dominates*
10.42
10.73 0.31 Dominates*
ted with higher DALYs gained and lower costs than no circumcisionr adviral therapy; DALY, disability adjusted life-years.
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76 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 0 - 7 9ty analyses, follows theWHO health economists’ recommen-
ations for economic evaluation and priority setting [35].
The model adopted a simplistic representation of the risk
f acquiring HIV infection among circumcised and uncircum-
ised adult males. The main limiting assumption of the static
odel includes the use of non-dynamic process at the level of
he risk of each sexual encounter, which could lead to a large
nderestimate of benefit and cost utility. Similarly, the model
ould underestimate cost effectiveness of AMC for prevention
f HIV, because we assume no direct benefit to the female
artners. However, a recent meta-analysis [36] of data from
ne randomized controlled trial and six longitudinal studies
ound little evidence that AMC directly reduces risk of HIV in
omen (pooled risk ratio  0.80; 95% CI 0.53 to 1.36). The au-
hors of this meta-analysis [36] cautioned that effect male-to-
emale HIV prevention cannot be ruled out. In addition, the
odel did not account for the impact of risk compensation
hat may be associated with AMC. It is not clear how AMCwill
ead to risk compensation (i.e., circumcised men engaging in
iskier sex behavior due to false sense of protection). Several
rials found no compelling evidence of increased HIV risk sex-
al behaviors among circumcised men [4,5,37,38].
Another limitation includes uncertainty in parameter
alues and the demonstrated sensitivity of the results to
hanges in some parameter values. All probabilities and
tilities used to populate the model are estimates derived
ig. 6 – Tornado plot for incremental disability adjusted life-
he red bars represent the best-case scenario.rom the literature. Each of those estimates carries inherent ancertainty. However, the uncertainty in the evidence base
as reflected in the model. To simultaneously assess the
mplications of uncertainty in all elements of evidence, we
sed probabilistic analysis to establish the decision uncer-
ainty associated with whether to implement AMC on a
arge scale [17]. This informs decision makers about the
robability of AMC being the most cost effective is condi-
ional on the value that the decision maker places on a unit
f health gain. The use of a decision-tree model allowed us
o extrapolate clinical outcomes beyond the duration of the
xisting clinical trials. Models inevitably serve as simplified
pproximations of the true nature. For simplicity we com-
ared the AMC to no AMC option. In reality, there are other
IV-prevention interventions options. An additional limita-
ion is that the lifetime costs of treating HIV were estimated
ased upon 2003 cost data [39]. It is possible that significant
hanges in treatment costs and practices have occurred
ince then. To address this limitation, we inflated the cost
ata to 2008 US pricing parity index. We did not include
roductivity losses due to mortality and morbidity – we as-
umed that these losses were incorporated in the DALY
easures.
omparison with other studies
his analysis supports conclusions of previous economic evalu-
s (DALY). The blue bars represent the worst-case scenario;yeartions [11–15] that AMCwould offer a cost-effective approach to
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77V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 0 - 7 9he prevention of heterosexual acquisition of HIV in men. For
xample, Gray et al. [14] estimated the cost perHIA over 10 years
ould range from $2808with 60% circumcision efficacy, to $4173
ith 40% circumcision efficacy. Kahn et al. [15] estimated cost
er HIA over 20 years at $193, and also reported that the results
ere sensitive to the cost of AMC, cost of avertedHIV treatment,
Fig. 7 – Incremental cost-effectiveness plane for aduFig. 8 – Cost-effectiveness acceptability curve for adult mhe protective effect of AMC, and HIV prevalence. Auvert et al.
11] found that the estimated costs per HIA over 10 and 20 years
ere $351 ($271 to $473) and $174 ($138 to $232). The net savings
ver 20 years was estimated at $2.4 billion (95% percentile inter-
al 1.5 to3.5). Fienoetal. 2008 [13] estimated thecostperHIVover
0 years at $390. Bollinger et al. [12] estimated cost per HIV and
le circumcision versus no adult male circumcision.lt maale circumcision versus no adult male circumcision.
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78 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 0 - 7 9et savings over 17 years with 60% circumcision efficacy at $642
nd $10,616 respectively.
These findings are comparable with other prevention and
reatment strategies in developing countries in terms of eco-
omic criteria [40]. Recent reviews of HIV prevention cost ef-
ectiveness suggest a range of US$10 to more than $10,000 per
IA [41,42]. South African studies on the cost effectiveness of
IV interventions focus onmother-to-child transmission pre-
ention interventions (with results ranging from cost saving if
djusted for averted medical care cost to $2492 per HIA) [43–
6] and the cost effectiveness of ongoing antiretroviral ther-
py [47,48]. Provision of the female condom to sex workers
as found to be cost saving if adjusted for averted medical
are costs [49]. A study of rescreening for HIV during late preg-
ancy found net savings [46], and another study found that
argeted sexually-transmitted infection treatment in sex
orkers costs US$78 per DALY [50].
onclusion
n conclusion, the results of this analysis suggest that AMC
an be regarded as cost saving. There is also little uncertainty
ssociatedwith this decision. The decisionmakers can be cer-
ain that the probability that AMC is cost effective is above 0.96
t a threshold value of US$150 and remains high over a wide
ange of threshold values. On these grounds, AMC may be
een as a promising new form of strategy for prevention of
eterosexual acquisition of HIV in men. However, our enthu-
iasmmust be tempered by the fact that AMCdoes not provide
omplete protection against HIV. In addition, there is no de-
nitive evidence that male circumcision reduces the risk of
IV transmission from men to women [36], or between men
ho have sex with men [51]. Thus, AMC should never replace
ther knownmethods of HIV prevention and should always be
onsidered as part of a comprehensive HIV prevention pack-
ge, which included: promoting delay in the onset of sexual
elations, unprotected penetrative sex, reduction in the num-
er of sexual partners, providing and promoting correct and
onsistent use of male and female condoms, providing HIV
esting and counselling services, and providing services for
he treatment of sexually-transmitted infections.
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